According to TipRanks, Moussatos is an analyst with an average return of -7.9% and a 33.02% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Aquestive Therapeutics, and Liquidia Technologies.
Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $81.71, implying a 49.21% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $76.00 price target.
PCRX market cap is currently $2.57B and has a P/E ratio of 70.22.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PCRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
Read More on PCRX:
- U.S. Department of Energy Loan Programs Office Invites Eos Energy Enterprises, Inc. Into Due Diligence
- Credit Suisse Sticks to Its Sell Rating for Portland GE (POR)
- Pacira Pharmaceuticals (PCRX) Receives a Buy from Needham
- Verizon commissions mural in Fort Worth as part of #ACallForKindness
- Volta Finance Limited: Net Asset Value as at 31 August 2022